Edit |   |
---|---|
Antigenic Specificity | CD262, Human (Drozitumab biosimilar) |
Clone | Drozitumab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG1 lambda |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | ELISA, FCM, IP, FuncS, IF, Neut |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human CD262 Recombinant Antibody (Drozitumab). Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Drozitumab was developed by Genentech. Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response. |
Immunogen | n/a |
Other Names | Anti-CD262 Recombinant Antibody, Research Grade Drozitumab, Anti-Human CD262 Recombinant Antibody(Drozitumab), PRO95780, anti-DR5, rhuMAb DR5, Antibody Drug Analogues, Monoclonal Antibody, YR1229, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 912628-39-8 |
Catalog # | YR1229 |
Price | please inquire |
Order / More Info | CD262, Human (Drozitumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |